[go: up one dir, main page]

BRPI0923859B8 - composição de agente de diagnóstico, e, método para a produção das nanopartículas - Google Patents

composição de agente de diagnóstico, e, método para a produção das nanopartículas

Info

Publication number
BRPI0923859B8
BRPI0923859B8 BRPI0923859A BRPI0923859A BRPI0923859B8 BR PI0923859 B8 BRPI0923859 B8 BR PI0923859B8 BR PI0923859 A BRPI0923859 A BR PI0923859A BR PI0923859 A BRPI0923859 A BR PI0923859A BR PI0923859 B8 BRPI0923859 B8 BR PI0923859B8
Authority
BR
Brazil
Prior art keywords
nanoparticles
production
composition
diagnostic agent
methods
Prior art date
Application number
BRPI0923859A
Other languages
English (en)
Inventor
Edgar Colborn Robert
John Bonitatibus Peter
Soliz Torres Andrew
Ernest Marino Michael
David Butts Matthew
Kulkarni Amit
C Bales Brian
Allan Hay Bruce
Original Assignee
Gen Electric
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/344,604 external-priority patent/US20100166664A1/en
Priority claimed from US12/344,608 external-priority patent/US8574549B2/en
Priority claimed from US12/344,606 external-priority patent/US8728529B2/en
Application filed by Gen Electric, Ge Healthcare Ltd filed Critical Gen Electric
Publication of BRPI0923859A2 publication Critical patent/BRPI0923859A2/pt
Publication of BRPI0923859B1 publication Critical patent/BRPI0923859B1/pt
Publication of BRPI0923859B8 publication Critical patent/BRPI0923859B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1848—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a silane
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Compounds Of Iron (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

NANOPARTÍCULA, COMPOSIÇÃO, MÉTODOS PARA A PRODUÇÃO DAS NANOPARTÍCULAS E DE USO, E, USO DE NANOPARTÍCULAS. São apresentadas nanopartículas (10) funcionalizadas com pelo menos um radical zuiteriônico, e composições constituídas pelas referidas nanopartículas. As nanopartículas (10) têm características que resultam em retenção mínima das partículas no corpo, comparado com outras nanopartículas. A nanopartícula (10) é composto por um núcleo (20), tendo uma superfície do núcleo (30) essencialmente isenta de sílica,e um invólucro (40) ligado na superfície do núcleo (30). O invólucro (40) é constituído pelo menos por um radical zuiteriônico funcionalizado por silano. Além disso, são apresentados métodos de produção das referidas nanopartículas e métodos para a sua utilização como agentes de diagnóstico.
BRPI0923859A 2008-12-29 2009-12-18 composição de agente de diagnóstico, e, método para a produção das nanopartículas BRPI0923859B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/344,604 US20100166664A1 (en) 2008-12-29 2008-12-29 Nanoparticle contrast agents for diagnostic imaging
US12/344608 2008-12-29
US12/344606 2008-12-29
US12/344,608 US8574549B2 (en) 2008-12-29 2008-12-29 Nanoparticle contrast agents for diagnostic imaging
US12/344,606 US8728529B2 (en) 2008-12-29 2008-12-29 Nanoparticle contrast agents for diagnostic imaging
US12/344604 2008-12-29
PCT/EP2009/067468 WO2010076237A2 (en) 2008-12-29 2009-12-18 Nanoparticle contrast agents for diagnostic imaging

Publications (3)

Publication Number Publication Date
BRPI0923859A2 BRPI0923859A2 (pt) 2015-07-28
BRPI0923859B1 BRPI0923859B1 (pt) 2020-09-15
BRPI0923859B8 true BRPI0923859B8 (pt) 2022-10-25

Family

ID=42246275

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923859A BRPI0923859B8 (pt) 2008-12-29 2009-12-18 composição de agente de diagnóstico, e, método para a produção das nanopartículas

Country Status (11)

Country Link
EP (1) EP2379118B1 (pt)
JP (1) JP6063627B2 (pt)
KR (2) KR101999853B1 (pt)
CN (2) CN102333547A (pt)
AU (1) AU2009334868B2 (pt)
BR (1) BRPI0923859B8 (pt)
CA (1) CA2748408C (pt)
ES (1) ES2647567T3 (pt)
MX (1) MX2011007058A (pt)
RU (1) RU2526181C2 (pt)
WO (1) WO2010076237A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101276693B1 (ko) 2010-10-29 2013-06-19 포항공과대학교 산학협력단 양쪽성 이온을 가진 나노입자 표면 개질용 표면 분자체의 합성과 그 응용
JP5790346B2 (ja) * 2011-02-10 2015-10-07 信越化学工業株式会社 アミノ酸変性シラン化合物の製造方法
KR20130045647A (ko) * 2011-10-26 2013-05-06 한국기초과학지원연구원 양쪽성 이온으로 코팅된 자기공명영상 조영제
JP6475618B2 (ja) * 2012-08-23 2019-02-27 ゼネラル・エレクトリック・カンパニイ 画像診断用のナノ粒子組成物
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
EP3195331B1 (en) * 2014-09-15 2021-05-26 Massachusetts Institute of Technology Nanoparticles for magnetic resonance imaging applications
WO2016167097A1 (ja) * 2015-04-15 2016-10-20 株式会社Kri ベタイン系ケイ素化合物及びその製造方法並びに親水性コーティング組成液及びコーティング膜
JP2017226759A (ja) * 2016-06-22 2017-12-28 株式会社Kri 修飾金属酸化物ゾル及び親水性コーティング組成物
JP6531124B2 (ja) * 2016-10-07 2019-06-12 株式会社Kri スルホベタイン系ケイ素系化合物の製造方法
WO2018070734A1 (ko) * 2016-10-14 2018-04-19 서울대학교산학협력단 코어쉘 구조를 포함하는 조영 효과 및 조직 접착 특성을 가지는 표지물질 및 이의 제조방법
BR112019027478A2 (pt) * 2017-06-28 2020-07-07 Riken nanopartículas, agente de contraste para imagens por ressonância magnética contendo o mesmo e o composto ligante
US20190001001A1 (en) * 2017-07-03 2019-01-03 General Electric Company Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance
JP7091129B2 (ja) * 2018-04-27 2022-06-27 キヤノン株式会社 粒子、及びその製造方法
CA3124753A1 (en) 2018-12-27 2020-07-02 Astellas Pharma Inc. Method for producing nanoparticle having metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded
CN111450258B (zh) * 2019-01-21 2022-08-02 沈阳药科大学 一种促进蛋白药物跨黏液渗透的口服给药系统及其制备
EP4090483A1 (en) * 2020-01-14 2022-11-23 Seinberg, Liis Metal-based core nanoparticles, synthesis and use
TWI864239B (zh) * 2020-03-27 2024-12-01 日商第一工業製藥股份有限公司 電解質及蓄電元件

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238767A1 (en) * 2004-12-17 2009-09-24 Koninklijke Philips Electronics, N.V. Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy
US7462446B2 (en) * 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070292688A1 (en) * 2005-08-18 2007-12-20 Eastman Kodak Company Silylamine modified nanoparticulate carriers
US20070098640A1 (en) * 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging
US10087082B2 (en) * 2006-06-06 2018-10-02 Florida State University Research Foundation, Inc. Stabilized silica colloid
TWI321133B (en) * 2006-08-01 2010-03-01 Univ Kaohsiung Medical Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol)
US20110045081A1 (en) * 2007-10-12 2011-02-24 Benedikt Steitz Magnetic, paramagnetic and/or superparamagnetic nanoparticles

Also Published As

Publication number Publication date
AU2009334868A1 (en) 2011-07-07
AU2009334868B2 (en) 2015-11-05
ES2647567T3 (es) 2017-12-22
CA2748408C (en) 2018-12-04
CN102333547A (zh) 2012-01-25
KR20110107329A (ko) 2011-09-30
CN107029250B (zh) 2023-08-08
KR101999853B1 (ko) 2019-07-12
BRPI0923859B1 (pt) 2020-09-15
EP2379118B1 (en) 2017-10-18
MX2011007058A (es) 2011-07-28
RU2526181C2 (ru) 2014-08-20
CA2748408A1 (en) 2010-07-08
KR20170059491A (ko) 2017-05-30
CN107029250A (zh) 2017-08-11
RU2011126275A (ru) 2013-02-10
WO2010076237A3 (en) 2011-02-03
WO2010076237A2 (en) 2010-07-08
EP2379118A2 (en) 2011-10-26
BRPI0923859A2 (pt) 2015-07-28
JP6063627B2 (ja) 2017-01-18
JP2012513963A (ja) 2012-06-21

Similar Documents

Publication Publication Date Title
BRPI0923859B8 (pt) composição de agente de diagnóstico, e, método para a produção das nanopartículas
BRPI0921830A8 (pt) Composição para tratamento bucal compreendendo sílica fundida
AR043446A1 (es) Agentes dispersantes en nanocompuestos
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
BR112015010395A2 (pt) composição para tratamento da pele com enxágue
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
AR096100A2 (es) Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hiv
AR067364A1 (es) Formulaciones solidas de artropodicidas de carboxamida
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
CL2009000573A1 (es) Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.
BR0314827A (pt) Processo para a produção de estruturas opalinas inversas
AR084582A1 (es) Composiciones fluidas, metodo
CO6680609A2 (es) Composición acuosa que contiene bromhexina
BR112015001672A2 (pt) microcápsulas com distribuição de tamanho de partícula, suspensão de microcápsulas e uso das microcápsulas
BR112014013923A8 (pt) método para produção de mulita percolada num corpo de material, mulita percolada, uso da mulita percolada e corpo de material
BR112016013195A2 (pt) Composições para a higiene bucal compreendendo carbonato de cálcio e uma argila
BR112012029454A2 (pt) trilho de guia para um sistema de elevador, e, sistema de elevador
BRPI0620800A2 (pt) uso de nano partículas compreendendo uma matriz de pelo menos uma proteína na qual pelo menos um agente ativo anti neoplástico é embutido
BR112013003002A2 (pt) composição contendo aditivo polar e agente quelante útil no hidroprocessamento de suprimentos hidrocarbonetos e método de sua produção e utilização
CO6280418A2 (es) Mezcla de yeso para formar un compuesto de alta resistencia para pisos
BR112015010392A2 (pt) composição para tratamento de pele
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
UY33005A (es) Celulosa microfibrosa con una distribucion del tamaño de las particulas que le permite ser utilizada en composiciones surfactantes estructuradas
BRPI0414438A (pt) método para preparar uma dispersão estável de óxido de metal em água, e, composição
BRPI0802405A2 (pt) agente de liberação de molde livre de solvente e sua aplicação na preparação de artigos moldados de poliuretano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B25A Requested transfer of rights approved

Owner name: GE HEALTHCARE LIMITED (GB)